Vaxart will welcome questions and answers from investors We

The management will discuss the progress of its programs, the proposals for a general meeting of shareholders

Webcast to be held June 22 at 1 p.m. ET

SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) — Vaxart, Inc. (VXRT) today announced that it will host a Q&A webcast with investors and analysts on Wednesday, June 22, 2022, at 1:00 p.m. Eastern Time. During the webcast, Andrei Floroiu, President and CEO, Dr. Sean Tucker, Senior Vice President and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will provide an overview of the company’s oral vaccine programs.

The Company will respond to written questions from investors and analysts. Please visit the webcast link to RSVP and submit written questions. Questions can also be submitted in advance to [email protected].

A replay of the webcast will be available on the Investors page of the Company’s website at approximately two hours after the end of the event.

As previously announced, Vaxart’s 2022 Annual Meeting of Shareholders has been rescheduled to Wednesday, July 6, 2022 at 12:30 p.m. EST. Vaxart encourages all shareholders of record on April 11, 2022 to vote their shares or change their votes in favor of all proposals submitted to the annual meeting by 11:59 p.m. Eastern Time on July 5, 2022.

About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle stick injury. Vaxart believes that its proprietary tablet vaccine delivery platform is suitable for delivering recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include vaccines in tablet form designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine against human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed extensive domestic and international patent applications covering its proprietary technology and designs for oral vaccination using adenoviruses and TLR3 agonists.

Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, outlook, plans and objectives, results of preclinical and clinical trials, commercialization agreements and licenses, as well as that management’s beliefs and expectations are forward-looking statements. These forward-looking statements may be accompanied by words such as “should”, “believe”, “could”, “potential”, “will”, “expect”, “anticipate”, “plan” and other terms and conditions of meaning similar. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data; and Vaxart’s expectations regarding the efficacy of its product candidates. Vaxart may not actually achieve the plans, achieve the intentions or meet the expectations or projections disclosed in any forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from Vaxart’s forward-looking statements, including uncertainties inherent in research and development, including the ability to achieve anticipated clinical results, start dates and/or or completion of clinical trials, dates of regulatory submission, dates of regulatory approval and/or initiation dates, as well as the possibility of new adverse clinical data and further analysis of existing clinical data; the risk that clinical trial data will be subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design and results of clinical studies; decisions of regulatory authorities impacting labeling, manufacturing processes and safety that could affect the availability or commercial potential of any product candidates, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-US regulatory authorities; that, even if approved by the FDA or non-US regulatory authorities, Vaxart’s product candidates may not achieve widespread market acceptance; that a Vaxart collaborator may not reach the development and commercial milestones; that Vaxart or its partners may experience manufacturing problems and delays due to events within or beyond the control of Vaxart or its partners; production difficulties, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including product candidate stability and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain and enforce necessary patents and other intellectual property protection; that Vaxart’s capital resources may be insufficient; Vaxart’s ability to resolve outstanding legal issues; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if any; the impact of government health care proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s quarterly and annual reports filed with the SEC. Vaxart undertakes no obligation to update forward-looking statements, except as required by law.



Source link

Comments are closed.